Schering’s and Novartis’ New Co-Promotion Agreement for PTK/ZK
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 57 (Table of Contents)
Published: 5 Mar-2005
DOI: 10.3833/pdr.v2005.i57.717 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Schering and Novartis formed a new co-promotion agreement for PTK787/ZK 222584 (PTK/ZK), a small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinases inhibitor for all oncology indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS